#efsitora
LightNews LightNews
nejm.org
Daily insulin injections can be a burden for patients with type 2 diabetes. Insulin efsitora is a new basal insulin that can be given once weekly. Research findings comparing efsitora with degludec are summarized in a new Quick Take video. youtu.be/miNU6siDB1E

#EndoSky #MedSky
Insulin Efsitora versus Degludec in Type 2 Diabetes | NEJM
YouTube video by NEJM Group
youtu.be
December 13, 2024 at 8:04 PM
medpagetoday.com
The FDA approved the once-weekly basal insulin efsitora (Onswik), drugmaker Eli Lilly announced on Thursday.
https://www.medpagetoday.com/endocrinology/diabetes/123153
FDA Approves Efsitora Weekly Insulin for Type 2 Diabetes
Approval marks the second once-weekly basal insulin for this population
www.medpagetoday.com
September 25, 2026 at 8:14 PM
redgdps.bsky.social
Nuevas Insulinas semanales en #congresoRedgdps con @GMNdoc #GelyAlvarez
#Efsitora
November 21, 2024 at 9:57 AM
nejm.org
In the QWINT-2 phase 3 trial, adults with type 2 diabetes who had not previously received insulin were assigned to receive once-weekly efsitora or once-daily degludec. Efsitora was noninferior to degludec in reducing glycated hemoglobin levels. nej.md/3Xuarje

#MedSky
The New England Journal of Medicine Insulin Efsitora versus Degludec in Type 2 Diabetes A PLAIN LANGUAGE SUMMARY Visual representation of daily insulin injections for a person with type 2 diabetes. Read the full Plain Language Summary at NEJM.org.
December 18, 2024 at 1:59 PM
Once weekly insulin seems to have similar outcomes to degludec - could help with patient compliance, but wonder what the $$$ will be #medsky

www.nejm.org/doi/full/10....
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment | NEJM
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a 52...
www.nejm.org
December 17, 2024 at 12:14 AM
sstrumello.bsky.social
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with Type 2 diabetes @prnewswire.bsky.social www.prnewswire.com/news-release...
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
/PRNewswire/ -- Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a...
www.prnewswire.com
September 24, 2026 at 5:46 PM
nkov.bsky.social
www.medscape.com/viewarticle/...
FDA Approves Efsitora Once-Weekly Basal Insulin Injection
The approval adds a second long-acting, injectable option for the treatment of type 2 diabetes.
www.medscape.com
September 27, 2026 at 12:22 AM
nejm.org
New in the December 12, 2024, issue of NEJM:

PCI in Patients Undergoing TAVI (NOTION-3 study) nej.md/3AH5WJo

Insulin Efsitora vs. Degludec in Type 2 Diabetes (QWINT-2 phase 3 trial) nej.md/3Xuarje

Bedaquiline Monotherapy in Multibacillary Leprosy nej.md/3ZQUjsn

#MedSky
Images and descriptions of what's available on NEJM.org this week
December 12, 2024 at 2:20 PM
mdspirenews.bsky.social
💉 FDA approves once-weekly insulin for adults with type 2 diabetes.

Four phase 3 trials found insulin efsitora alfa-gobe noninferior for HbA1c reduction vs once-daily basal insulin comparators.

Read more: https://ow.ly/hMoS50ZRrx9

#Diabetes #FDA
September 25, 2026 at 2:55 PM
easdnews.bsky.social
Should everyone switch from once-daily insulins to #icodec or #efsitora?

#EASD Board Member Julia Mader lets you know who would benefit from once-weekly #insulins, discussing the latest data (#QWINT2) in this Expert Insights ep.

🎥👉https://easd-elearning.eu/Expert_Insights_14.html

#diabetes
January 22, 2025 at 10:38 AM
shihcheng.bsky.social
NEJM: A 52-week phase 3 trial finds once-weekly efsitora alfa effective for Type 2 diabetes. Adults show improvement without prior insulin use. PMID:40548694, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2502796 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2502796
No description available
doi.org
September 9, 2025 at 12:10 PM
nejm.org
In the QWINT-1 phase 3 trial, once-weekly insulin efsitora, administered in a fixed-dose regimen, was noninferior to glargine in reducing hemoglobin levels in patients with type 2 diabetes who had not previously received insulin. Full trial results and Research Summary: nej.md/4jX5R59
The New England Journal of Medicine Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes A Research Summary based on Rosenstock J et al. | 10.1056/NEJMoa2502796 | Published on June 22, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
July 27, 2025 at 1:00 PM
medicalprofref.bsky.social
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApprovals https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
Once-Weekly Basal Insulin Onswik Approved for Type 2 Diabetes
Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.
www.empr.com
September 24, 2026 at 8:38 PM
medicalprofref.bsky.social
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApproval https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
Once-Weekly Basal Insulin Onswik Approved for Type 2 Diabetes
Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.
www.empr.com
September 24, 2026 at 7:38 PM
nejm.org
New in the July 24, 2025, issue of NEJM:

Fixed-Dose Insulin Efsitora in Type 2 Diabetes (QWINT-1 phase 3 trial) nej.md/4jX5R59

Trastuzumab Deruxtecan in Gastric Cancer (DESTINY-Gastric04 phase 3 trial) nej.md/4k1dwjN

#MedSky
Images and descriptions of what's new on NEJM.org this week
July 24, 2025 at 1:25 PM
nejm.org
In QWINT-1 phase 3 trial, once-weekly insulin efsitora, administered in a fixed-dose regimen, was noninferior to glargine in reducing hemoglobin levels in patients with type 2 diabetes who had not previously received insulin. Full trial results: nej.md/4jX5R59

#ADASciSessions
A graph showing the least-squares mean glycated hemoglobin level over time among all eligible participants who had adhered to the trial intervention without using rescue medication (efficacy estimand), as well as the least-squares mean glycated hemoglobin level at week 52 among all eligible participants, regardless of adherence to the trial regimen or the use of rescue medication.
June 22, 2025 at 6:38 PM
rankednews.bsky.social
New type 2 diabetes jab could cut number of injections by 86 per cent: The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending insulin efsitora alfa, a weekly treatment for type 2 diabetes. This new jab, also branded … https://ranked.news/1267708?u=b
Article image
August 20, 2026 at 6:00 AM
nejm.org
📖 Further reading 
Original Article by J. Rosenstock et al.: Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy (QWINT-1 trial) nej.md/4jX5R59
February 15, 2026 at 5:01 PM
medpedshosp.medsky.social
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

www.thelancet.com/journals/lan...
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
Efsitora is a well tolerated and efficacious once-weekly alternative to daily basal insulin, with a reduced injection frequency, for the treatment of adults with type 2 diabetes.
www.thelancet.com
June 27, 2025 at 6:44 PM
biobonanos.bsky.social
Lilly's once-weekly insulin, efsitora alfa, met the primary endpoints in two Phase III studies that compared it with once-daily versions: investor.lilly.com/news-release...
investor.lilly.com
September 5, 2024 at 11:59 AM
anna1900.bsky.social
Efsitora alfa was tested in two phase 3 trials for 1 onDM1. one in pts w/ type 1 DM and one in those with type 2. Results presented at the European Association for the Studyof DM show that the wky injection is as effective as dly long-acting basal insulins.
December 5, 2024 at 2:49 PM
nejm.org
QWINT-1 phase 3 trial: Basal insulin is recommended for patients with type 2 diabetes that is not well controlled with noninsulin glucose-lowering agents, but daily injections can be burdensome. Research findings on weekly basal insulin are summarized in a new Quick Take video. nej.md/4f4zdhf
An illustration of trial participants with type 2 diabetes who received either once-weekly insulin efsitora alfa in a fixed-dose regimen or once-daily insulin glargine U100 with weekly sliding-scale dose adjustments
July 30, 2025 at 4:05 PM
rankednews.bsky.social
Eli Lilly: New type 2 diabetes jab could slash number of injections to one a week: The National Institute for Health and Care Excellence (Nice) has recommended a new weekly insulin treatment for type 2 diabetes, known as Onswik (insulin efsitora alfa) and manufacture… https://ranked.news/1268984?u=b
Article image
August 21, 2026 at 12:08 AM
mimsonline.bsky.social
The first once-weekly basal insulin (efsitora alfa, also known as Onswik) has been provisionally recommended by NICE for people with type II diabetes.

Read more on MIMS
buff.ly/yhyZCPB
First once-weekly insulin recommended by NICE
NICE has recommended insulin efsitora alfa for people with type II diabetes, in final draft guidance published today.
www.mims.co.uk
August 20, 2026 at 2:00 PM
epocanegocios.bsky.social
Uma nova insulina experimental pode, um dia, substituir as injeções diárias por semanais para pessoas com diabetes
Insulina semanal experimental funciona tanto quanto doses diárias, apontam testes clínicos
Farmacêutica Eli Lilly diz que estudo mostrou que pacientes com diabetes tipo 2 viram seus níveis de hemoglobina glicada cair em média 1,31% após 52 semanas com doses de efsitora
epocanegocios.globo.com
September 5, 2024 at 12:41 PM